Sufentanil as Adjuvant of Balanced Anesthesia

Kangbuk Samsung Hospital

Status

Completed

Conditions

Anesthesia

Treatments

Drug: Remifentanil

Drug: Sufentanil

Study type

Interventional

Funder types

Other

Identifiers

NCT03868111

2019-02-001

Details and patient eligibility

About

The aim of the study was to compare the efficacy and safety between sufentanil and remifentanil as an adjuvant of balanced general anesthesia.

Full description

The investigators hypothesized that sufentanil would reduce postoperative pain than remifentanil without prolonging recovery times in minor laparoscopic surgery when administered equivalent antinociceptive doses during surgery. Intraoperative opioid administration for equivalent nociception-antinociception balance could be achieved via surgical pleth index (SPI)-guided analgesia. This study was designed to compare the efficacy and safety between sufentanil and remifentanil as an adjuvant of balanced anesthesia in patients undergoing laparoscopic cholecystectomy under SPI-guided opioid administration.

Enrollment

66 patients

Sex

All

Ages

19 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients aged between 19 and 65 years
Patients with American Society of Anesthesiologists physical status I or II
Patients scheduled for elective laparoscopic cholecystectomy under balanced general anesthesia for benign cholecystic diseases
Patients obtaining written informed consent

Exclusion criteria

Patients with asthma or hypertension
Patients with an inability to express their pain accurately
Patients with an inability to understand the pain scale
Patients with chronic abdominal pain or chronic pain syndrome
Patients who required to convert to laparotomy from laparoscopic surgery
Patients who required to receive incidental lower abdominal procedures owing to adhesion, injury, or other incidental findings at the lower abdominal cavity
Patients with a history of drug or alcohol abuse
Pregnant women